Ligand Pharmaceuticals IncorporatedLGNDNASDAQ
Loading
Year-over-year SG&A expense growth
Percentile
P18
Within normal range
vs 5Y Ago
-0.1x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -12.02% |
| Q3 2025 | 41.00% |
| Q2 2025 | 7.31% |
| Q1 2025 | -26.57% |
| Q4 2024 | 4.62% |
| Q3 2024 | 38.88% |
| Q2 2024 | 60.93% |
| Q1 2024 | -31.52% |
| Q4 2023 | 9.12% |
| Q3 2023 | 29.85% |
| Q2 2023 | 3.98% |
| Q1 2023 | -45.32% |
| Q4 2022 | 33.06% |
| Q3 2022 | 23.45% |
| Q2 2022 | 1.35% |
| Q1 2022 | -32.76% |
| Q4 2021 | 39.46% |
| Q3 2021 | -13.55% |
| Q2 2021 | 16.60% |
| Q1 2021 | -58.06% |
| Q4 2020 | 100.28% |
| Q3 2020 | 49.17% |
| Q2 2020 | 8.69% |
| Q1 2020 | -9.86% |
| Q4 2019 | 7.90% |
| Q3 2019 | -13.36% |
| Q2 2019 | -0.85% |
| Q1 2019 | -0.67% |
| Q4 2018 | 15.88% |
| Q3 2018 | 3.65% |
| Q2 2018 | 21.60% |
| Q1 2018 | -1.37% |
| Q4 2017 | 10.20% |
| Q3 2017 | 7.38% |
| Q2 2017 | -10.56% |
| Q1 2017 | 10.50% |
| Q4 2016 | 5.09% |
| Q3 2016 | -8.13% |
| Q2 2016 | 0.56% |
| Q1 2016 | 10.26% |